The VK2735 peptide has emerged as one of the most closely watched compounds in the metabolic drug pipeline. Developed by Viking Therapeutics, this dual GLP-1/GIP receptor agonist has produced weight loss results in clinical trials that rival or exceed those of approved medications like tirzepatide, positioning it as a potential next-generation treatment for obesity and metabolic disease. With both injectable and oral formulations in late-stage clinical development, VK2735 represents a significant evolution in incretin-based pharmacology.

This guide consolidates the current state of VK2735 peptide research as of 2026. It covers the compound’s dual-agonist mechanism, Phase 1 and Phase 2 clinical trial data, comparison with retatrutide and tirzepatide, the significance of Viking’s oral formulation program, and the broader implications for the metabolic peptide landscape. Every data point references published trial results or official company disclosures.

For researchers already working with incretin receptor agonists, the retatrutide complete guide and tirzepatide research guide provide complementary data on the compounds most frequently compared to VK2735.

What Is VK2735? Mechanism and Pharmacology

VK2735 is a synthetic peptide designed to simultaneously activate two incretin hormone receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This dual-agonist approach builds on the therapeutic framework established by tirzepatide (Eli Lilly’s Mounjaro/Zepbound), which first demonstrated that targeting both GLP-1 and GIP receptors produces superior metabolic outcomes compared to GLP-1 agonism alone.

Viking Therapeutics engineered VK2735 to optimize receptor binding affinity, pharmacokinetic stability, and dosing convenience. The compound’s molecular structure incorporates modifications designed to extend its half-life in circulation, enabling once-weekly subcutaneous dosing in the injectable formulation. These structural refinements aim to balance maximal receptor activation with tolerability across the dose-escalation range.

GLP-1 Receptor Activation

The GLP-1 component of VK2735’s mechanism drives several well-characterized metabolic effects. GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and acts on hypothalamic satiety centers to reduce appetite. Research published in The New England Journal of Medicine established these effects as the pharmacological foundation shared by all GLP-1-based therapies, from semaglutide to liraglutide to tirzepatide.

GIP Receptor Activation

The GIP component adds a layer of metabolic modulation that GLP-1-only agonists lack. GIP receptor activation enhances insulin sensitivity in adipose tissue, promotes energy expenditure, and modulates lipid metabolism. In combination with GLP-1, GIP signaling appears to produce additive or synergistic effects on body weight reduction and glycemic control that exceed what either receptor alone can achieve.

Research published in Nature Metabolism has explored how dual GLP-1/GIP agonism may improve weight loss outcomes through distinct effects on fat oxidation and energy expenditure that GLP-1-only compounds do not fully engage. This mechanistic advantage is central to VK2735’s competitive positioning against single-agonist therapies.

Differentiation from Triple Agonists

While VK2735 targets two receptors, compounds like retatrutide target three — GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds hepatic fat oxidation and thermogenesis to the metabolic equation. This makes retatrutide a triple agonist with potentially broader metabolic effects, while VK2735 focuses on the GLP-1/GIP dual-agonist approach that has already been validated by tirzepatide’s clinical success.

For a detailed analysis of how dual and triple agonists compare, see the semaglutide vs retatrutide vs tirzepatide comparison guide.

VK2735 Clinical Trial Data: What Do the Results Show?

Viking Therapeutics has published clinical data from its VK2735 development program that has generated significant attention from both the research community and financial markets. The results position VK2735 as a potentially best-in-class dual GLP-1/GIP agonist.

Phase 1 Trial Results

The Phase 1 dose-escalation study evaluated VK2735’s safety, tolerability, and pharmacokinetic profile in healthy volunteers and overweight/obese subjects. Results demonstrated dose-dependent weight loss with a favorable tolerability profile across the tested dose range. The pharmacokinetic data confirmed VK2735’s suitability for once-weekly subcutaneous dosing, with consistent plasma levels maintained throughout the dosing interval.

Key findings included statistically significant body weight reductions even at the lowest active doses, supporting VK2735’s potent receptor binding affinity. Gastrointestinal adverse events — nausea, vomiting, and diarrhea — were the most common side effects, consistent with the class-wide tolerability profile of incretin-based therapies. These events were predominantly mild to moderate and decreased over time.

Phase 2 Trial Results (VENTURE)

The Phase 2 VENTURE trial delivered the results that placed VK2735 at the center of the metabolic drug conversation. In a randomized, double-blind, placebo-controlled study of adults with a BMI of 30 or greater, VK2735 demonstrated substantial weight loss across multiple dose cohorts over a 13-week treatment period.

Top-line results reported mean body weight reductions of up to 14.7 percent from baseline at the highest dose after only 13 weeks of treatment. This rate of weight loss exceeds the results typically seen with tirzepatide at comparable timepoints and approaches the trajectory needed to achieve 20+ percent weight loss over longer treatment durations — a threshold that would position VK2735 among the most effective anti-obesity compounds in development.

The VENTURE data also showed significant improvements in cardiometabolic risk markers, including reductions in waist circumference, improvements in lipid profiles, and reductions in markers of systemic inflammation. These secondary endpoints are critical for establishing the cardiovascular benefit profile that regulators increasingly require for anti-obesity drug approval.

Phase 3 Development

Based on the strength of Phase 2 results, Viking Therapeutics has advanced VK2735 into Phase 3 clinical development. The Phase 3 program is designed to provide the pivotal efficacy and safety data required for regulatory approval, with larger patient populations, longer treatment durations, and comprehensive assessment of durability of weight loss effects.

The Phase 3 timeline and study design will determine whether VK2735 can maintain its competitive weight loss results over 52 to 72-week treatment periods while preserving an acceptable safety and tolerability profile. These longer-duration data are essential because weight loss with GLP-1-based therapies typically continues to accrue through the first 40 to 60 weeks of treatment before reaching a plateau.

VK2735 Oral Formulation: Why Does It Matter?

One of VK2735’s most strategically significant features is Viking Therapeutics’ parallel development of an oral formulation alongside the subcutaneous injectable. An effective oral GLP-1/GIP agonist would address one of the most significant barriers to adoption of incretin-based therapies — the requirement for weekly self-injection.

Viking Therapeutics has reported positive Phase 1 data for the oral VK2735 formulation, demonstrating bioavailability sufficient to produce clinically meaningful drug exposures after oral administration. The oral formulation uses proprietary absorption-enhancing technology to overcome the peptide’s natural susceptibility to gastrointestinal degradation and limited intestinal permeability.

If the oral formulation advances successfully through Phase 2 and Phase 3 trials, it would provide VK2735 with a substantial competitive advantage over injectable-only competitors. The convenience of a daily pill versus a weekly injection could significantly expand the addressable patient population and improve treatment adherence — two factors that directly influence real-world effectiveness.

The oral formulation race includes competitors like orforglipron (Eli Lilly) and danuglipron (Pfizer), as well as Novo Nordisk’s amycretin. VK2735’s oral program is differentiated by its dual GLP-1/GIP mechanism, which theoretically provides the same mechanistic advantage over GLP-1-only oral compounds that injectable tirzepatide demonstrated over injectable semaglutide.

How Does VK2735 Compare to Retatrutide and Tirzepatide?

The metabolic peptide landscape in 2026 features several competing approaches to incretin-based weight loss. Understanding VK2735’s position requires direct comparison with the two compounds most frequently cited as benchmarks: retatrutide and tirzepatide.

The rate of weight loss is VK2735’s most compelling data point. Achieving approximately 14.7 percent weight loss in just 13 weeks suggests a trajectory that could match or exceed tirzepatide’s 72-week results if sustained over longer treatment periods. However, Phase 3 data will be needed to confirm whether this early rate of loss is maintained.

Retatrutide’s triple-agonist mechanism gives it a theoretical advantage through the added glucagon receptor activation, which drives hepatic fat oxidation and thermogenesis. Whether this translates into clinically superior outcomes over VK2735’s dual mechanism is an open question that ongoing Phase 3 trials will help answer.

For a deeper comparison of the competitive landscape, see the retatrutide vs tirzepatide comparison and the comprehensive best peptides for weight loss guide.

VK2735 Peptide Safety and Tolerability Profile

VK2735’s safety data from Phase 1 and Phase 2 trials is consistent with the established class profile of GLP-1-based therapies. The most commonly reported adverse events are gastrointestinal in nature — nausea, vomiting, diarrhea, and decreased appetite. These events are dose-dependent, most frequent during dose-escalation periods, and generally resolve or diminish with continued treatment.

Importantly, the VENTURE trial data showed that VK2735’s tolerability profile was manageable even at the highest efficacy doses. The proportion of patients discontinuing treatment due to adverse events was relatively low, suggesting that the dose-escalation schedule adequately mitigates the GI effects that commonly limit treatment with incretin agonists.

No significant signals for pancreatitis, thyroid C-cell tumors, or other class-associated safety concerns emerged in the clinical data reported to date. However, Phase 3 trials with larger patient populations and longer treatment durations will provide the comprehensive safety dataset needed for regulatory evaluation. Published reviews of incretin agonist safety profiles in The Lancet Diabetes & Endocrinology provide context for evaluating emerging safety data across this drug class.

What Does VK2735 Mean for the Research Peptide Landscape?

VK2735’s clinical development validates the dual GLP-1/GIP agonist approach as a leading paradigm in metabolic drug development. For the research community, several implications follow from Viking’s progress.

Mechanism validation. VK2735’s clinical data reinforces the finding that dual GLP-1/GIP agonism produces superior weight loss compared to GLP-1 agonism alone. This validation supports continued research into multi-receptor approaches to metabolic disease, including the triple agonism exemplified by retatrutide.

Oral peptide feasibility. Viking’s oral formulation program demonstrates that technically challenging oral peptide delivery is advancing toward clinical viability. Success here would reshape the competitive landscape by removing the injection barrier that limits current GLP-1 therapy adoption.

Research compound availability. While VK2735 itself is not available for independent research purchase, compounds with similar or overlapping mechanisms are. Researchers investigating dual and triple incretin agonism can access retatrutide and tirzepatide from PSPeptides for laboratory investigation of these receptor pathways.

Where to Buy Similar Mechanism Peptides for Research

VK2735 is in clinical development and not available for independent purchase. However, researchers studying dual and triple incretin agonism can access compounds with similar or overlapping mechanisms through PSPeptides.

Retatrutide provides the broadest receptor coverage, targeting GLP-1, GIP, and glucagon receptors simultaneously. Tirzepatide shares VK2735’s dual GLP-1/GIP mechanism and offers the advantage of extensive published clinical data for benchmarking research results.

Third-party Certificates of Analysis. Every batch is independently tested for purity, identity, and peptide content. COAs are published for every lot — researchers can verify quality before beginning experiments.

Same-day shipping from US warehouses. Orders placed before the daily cutoff ship the same business day. Domestic fulfillment keeps transit times short for temperature-sensitive compounds.

Complete supply bundles. PSPeptides stocks peptides alongside bacteriostatic water, insulin syringes, and alcohol swabs. One order covers everything needed to begin research immediately.

Flexible payment options. All major credit cards are accepted alongside Afterpay and Klarna for installment payments. No cryptocurrency requirements and no invasive identity verification.

Browse the complete metabolic peptide catalog at pspeptides.com/shop.

Understanding vk2735 peptide is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What is VK2735 and who makes it?

VK2735 is a dual GLP-1/GIP receptor agonist peptide developed by Viking Therapeutics for the treatment of obesity and metabolic disease. It activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors simultaneously, producing appetite suppression, improved glycemic control, and substantial weight loss. Viking is developing both injectable (once-weekly subcutaneous) and oral formulations, with the injectable version currently in Phase 3 clinical trials.

How much weight loss does VK2735 produce?

In the Phase 2 VENTURE trial, VK2735 produced mean body weight reductions of up to approximately 14.7 percent from baseline at the highest dose after 13 weeks of treatment. This rate of weight loss exceeds what tirzepatide typically achieves at comparable timepoints and suggests the potential for 20+ percent total body weight reduction over longer treatment durations. Phase 3 data will confirm whether this early rate is sustained over 52 to 72 weeks.

How does VK2735 compare to retatrutide?

VK2735 and retatrutide share GLP-1 and GIP receptor agonism but differ in their additional targets. Retatrutide adds glucagon receptor activation (making it a triple agonist), which drives hepatic fat oxidation and thermogenesis. VK2735 focuses on the dual GLP-1/GIP approach and adds an oral formulation program that retatrutide lacks. Both compounds are in Phase 3 development. Researchers can compare their mechanisms using retatrutide and tirzepatide available from PSPeptides.

Can I buy VK2735 peptide for research?

VK2735 is a proprietary compound in clinical development by Viking Therapeutics and is not available for independent research purchase. Researchers investigating similar mechanisms can access retatrutide (triple GLP-1/GIP/glucagon agonist) and tirzepatide (dual GLP-1/GIP agonist) from PSPeptides with independent COA verification and same-day US shipping.

All PSPeptides products are sold exclusively for research and laboratory use.